Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Acquisitions & Divestments (2019 - 2025)

KalVista Pharmaceuticals' Change in Acquisitions & Divestments history spans 5 years, with the latest figure at $20.2 million for Q2 2025.

  • For Q2 2025, Change in Acquisitions & Divestments rose 30.56% year-over-year to $20.2 million; the TTM value through Apr 2025 reached $122.8 million, up 17.0%, while the annual FY2025 figure was $122.5 million, 16.74% up from the prior year.
  • Change in Acquisitions & Divestments for Q2 2025 was $20.2 million at KalVista Pharmaceuticals, down from $48.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $48.9 million in Q4 2024 and bottomed at $11.6 million in Q1 2024.
  • The 3-year median for Change in Acquisitions & Divestments is $32.5 million (2023), against an average of $30.3 million.
  • The largest YoY upside for Change in Acquisitions & Divestments was 50.24% in 2024 against a maximum downside of 15.77% in 2024.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $32.5 million in 2023, then soared by 50.24% to $48.9 million in 2024, then plummeted by 58.65% to $20.2 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Change in Acquisitions & Divestments are $20.2 million (Q2 2025), $48.9 million (Q4 2024), and $38.2 million (Q3 2024).